UDR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
UDR is not a good buy right now for an impatient buyer. The tape is technically weak (bearish MA stack and negative MACD), options positioning is skewed defensive/bearish (high put open interest), and pattern-based stats imply downside risk over the next month. While fundamentals are improving and some analysts are constructive, the current setup does not offer a clean momentum entry near resistance; I would wait for either a breakout above ~37.90–38.34 or a pullback toward ~36.48 support before considering a buy.
Trend/structure: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), signaling the broader downtrend is still intact. Momentum: MACD histogram is negative (-0.0704) though contracting (bearish momentum easing, but not reversed). RSI(6) at 52.86 is neutral, consistent with a weak/sideways bounce inside a larger downtrend. Levels: Pivot 37.191 (price ~37.15 is sitting right at pivot = indecision). Resistance at R1 37.902 then R2 38.34; support at S1 36.48 then S2 36.042. A failure to reclaim/hold above ~37.90 increases odds of revisiting 36.48. Stat-based forward bias (similar patterns): ~70% chance of ~-0.2% next day, +1.49% next week, and -5.57% next month—net skew negative over the near term.
Intellectia Proprietary Trading Signals
with strong net income and EPS growth.
Technical setup remains bearish (downtrend MA stack; MACD below zero), reducing odds of an immediate sustained rally.
Options positioning is defensive/bearish (high put open interest; elevated implied volatility).
Model/pattern projection indicates negative 1-month expectancy (-5.57%).
No supportive news flow in the last week to provide an immediate catalyst.
Analyst risk: Goldman Sachs reiterates Sell (PT $37.50), and JPMorgan recently downgraded to Underweight (PT $40), highlighting ongoing skepticism on relative value/upside.
Latest quarter: 2025/Q3. Revenue grew to $431.864M (+2.79% YoY), showing modest top-line growth. Profitability improved sharply: net income $39.198M (+83.17% YoY) and EPS $0.12 (+100% YoY). Gross margin slipped to 63.39% (-0.94% YoY), suggesting some cost/operating pressure even as earnings improved.
Recent trend: price targets have generally been nudged up since early January (UBS to $42; Truist to $42 with an upgrade; Goldman to $37.50 but maintained Sell). Late 2025 saw several target trims and at least one downgrade (JPMorgan to Underweight), indicating mixed conviction. Wall Street pros: improving REIT backdrop narrative (slowing new supply, steadier demand), supportive total return outlook from some brokers, and multiple Buy/Overweight ratings still in place. Wall Street cons: valuation/upside viewed as less compelling by bears, and some firms have shifted to more cautious stances (Underweight/Sell) despite target increases.
